PAP 2023: Corey Ford Discusses Questions from the State of the Industry Address at Access PAP 2023

Access to the GLP-1 will be streamlined, and starting July 1, will result in a limited-time $299 price for eligible self-pay patients.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

The collaborative research initiative will be focused on advancing approaches to enhance the therapeutic efficacy of regulatory T cells and tumor-infiltrating lymphocytes.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

Doubling down on patient access and support fundamentals will win out over Washington’s next move.

Many uninsured and underinsured individuals remain unaware of vital financial assistance programs for prescription costs, highlighting a critical need for increased awareness and resources.